Literature DB >> 35992619

Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

Carla S Coffin1, Scott K Fung2, Fernando Alvarez3, Curtis L Cooper4, Karen E Doucette5, Claire Fournier6, Erin Kelly7, Hin Hin Ko8, Mang M Ma9, Steven R Martin10, Carla Osiowy11, Alnoor Ramji12, Edward Tam13, Jean Pierre Villeneuve6.   

Abstract

Hepatitis B virus (HBV) infection is an important public health problem in Canada. In keeping with evolving evidence and understanding of HBV pathogenesis, the Canadian Association for the Study of Liver Disease periodically publishes HBV management guidelines. The goals of the 2018 guidelines are to (1) highlight the public health impact of HBV infection in Canada and the need to improve diagnosis and linkage to care, (2) recommend current best-practice guidelines for treatment of HBV, (3) summarize the key HBV laboratory diagnostic tests, and (4) review evidence on HBV management in special patient populations and include more detail on management of HBV in pediatric populations. An overview of novel HBV tests and therapies for HBV in development is provided to highlight the recent advances in HBV clinical research. The aim and scope of these guidelines are to serve as an up-to-date, comprehensive resource for Canadian health care providers in the management of HBV infection.
Copyright © 2018 Canadian Association for the Study of the Liver.

Entities:  

Keywords:  Association of Medical Microbiology and Infectious Disease (AMMI) Canada; Canadian Association for the Study of Liver Disease (CASL); guidelines; hepatitis B

Year:  2018        PMID: 35992619      PMCID: PMC9202759          DOI: 10.3138/canlivj.2018-0008

Source DB:  PubMed          Journal:  Can Liver J        ISSN: 2561-4444


  328 in total

1.  Meta-analysis: antiviral treatment for hepatitis D.

Authors:  C Triantos; M Kalafateli; V Nikolopoulou; A Burroughs
Journal:  Aliment Pharmacol Ther       Date:  2012-01-24       Impact factor: 8.171

2.  Seroprevalence of hepatitis B and C virus infections: Results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey.

Authors:  Michelle Rotermann; Kellie Langlois; Anton Andonov; Maxim Trubnikov
Journal:  Health Rep       Date:  2013-11       Impact factor: 4.796

3.  Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients.

Authors:  José M Sánchez-Tapias; Josep Costa; Antoni Mas; Miquel Bruguera; Juan Rodés
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

4.  Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial.

Authors:  J Wiegand; H Wedemeyer; A Franke; S Rößler; S Zeuzem; G Teuber; M Wächtler; U Römmele; B Ruf; U Spengler; C Trautwein; C T Bock; G M Fiedler; J Thiery; M P Manns; O Brosteanu; H L Tillmann
Journal:  J Viral Hepat       Date:  2013-12-11       Impact factor: 3.728

5.  The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age.

Authors:  M H Chang; H Y Hsu; H C Hsu; Y H Ni; J S Chen; D S Chen
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

6.  Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients.

Authors:  Guangjun Song; Ruifeng Yang; Huiying Rao; Bo Feng; Hui Ma; Qian Jin; Lai Wei
Journal:  J Med Virol       Date:  2016-08-31       Impact factor: 2.327

7.  A family cluster of an immune escape variant of hepatitis B virus infecting a mother and her two fully immunized children.

Authors:  M S Ho; C F Lu; J Kuo; Y C Mau; W H Chao
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

Review 8.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

Authors:  Aparna Schweitzer; Johannes Horn; Rafael T Mikolajczyk; Gérard Krause; Jördis J Ott
Journal:  Lancet       Date:  2015-07-28       Impact factor: 79.321

9.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

10.  Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety.

Authors:  M M Jonas; N R Little; S D Gardner
Journal:  J Viral Hepat       Date:  2008-01       Impact factor: 3.728

View more
  2 in total

1.  Seroprevalence of hepatitis B in previously undiagnosed patients: A community screening study.

Authors:  Daljeet Chahal; Joseph Gh Lee; Eric M Yoshida; Chris Lowe; Francis Ho; Vivian Sum; Peter Kwan
Journal:  Can Liver J       Date:  2022-05-09

2.  Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue.

Authors:  Alnoor Ramji; Karen Doucette; Curtis Cooper; Gerald Yosel Minuk; Mang Ma; Alexander Wong; David Wong; Edward Tam; Brian Conway; David Truong; Philip Wong; Lisa Barrett; Hin Hin Ko; Sarah Haylock-Jacobs; Nishi Patel; Gilaad G Kaplan; Scott Fung; Carla S Coffin
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.